isoSolutions Marketing & Management Inc. offers a wide range of products for nuclear medicine applications, from a variety of reliable suppliers, providing a one-stop shopping service as well as technical support.
worldwide in 2017
on time in 2017
Kevin Yang ⎜ Sep 12, 2018
This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low
imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted.
Jie Zang & Xinrong Fan & Hao Wang & Qingxing Liu & Jingnan Wang & Hui Li & Fang Li & Orit Jacobson & Gang Niu & Zhaohui Zhu & Xiaoyuan Chen
Info on purchasing Lu-177, please contact firstname.lastname@example.org.
Kevin Yang ⎜ Sep 6, 2018
Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, …
isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018.
The Chinese Society of Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from 2018–07–12 to 2018–07–15. We hope to see you there and we can arrange a time and place to meet if you wish.
Pennsylvania Convention Center, Headquarter Hotel: Philadelphia Marriott. isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)